title: Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women.
abstract: To clarify potential differences between denosumab (DNS) and bisphosphonates (BIS) in terms of bone density and bone metabolism, in a sample of postmenopausal women.
  
  
  
  A total of 113 postmenopausal women aged 53-66 years were treated with either DNS or BIS for 12 months. Bone densitometry and laboratory tests were compared between baseline and follow-up.
  
  
  
  Femoral neck BMD increased in both treatment-arms (FN-BMD, DNS: 0.69±0.07 g/cm2to 0.75±0.09 g/cm2; BIS: 0.69±0.06 g/cm2to 0.71±0.07 g/cm2; p≤0.001 in both cases). Lumbar spine BMD (LS-BMD) increased significantly only in the DNS-group (0.83±0.14 g/cm2to 0.89±0.14 g/cm2, p=0.0001). Only women under treatment with DNS had a significant increase in serum parathyroid hormone (PTH: 44.87±17.54 pg/mL to 53.27±15.77 pg/mL, p=0.04), independently of baseline vitamin D levels. DNS-administration resulted in higher increase from baseline in FN-BMD compared to BIS (DNS vs BIS: 8.7%±8.5 vs 3.8%±7.3, p=0.004). Finally, baseline 25OH vitamin D levels did not determine the extent of PTH-increase following administration of DNS- or BIS-treatment.
  
  
  
  Both treatments increased BMD, however, the effect of DNS on FN-BMD was superior compared to that of BIS. DNS-treatment increased serum PTH. Baseline 25OH vitamin D levels did not predict the extent of PTH increase at follow-up.
authors.affiliation: 2nd Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Aretaieio Hospital, 76 Vas. Sofias Ave, GR-11528, Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Augoulea
authors.forename: E
authors.initials: E
authors.lastname: Tsakonas
authors.forename: I
authors.initials: I
authors.lastname: Triantafyllopoulos
authors.forename: D
authors.initials: D
authors.lastname: Rizos
authors.forename: E
authors.initials: E
authors.lastname: Armeni
authors.forename: N
authors.initials: N
authors.lastname: Tsoltos
authors.forename: S
authors.initials: S
authors.lastname: Tournis
authors.forename: E
authors.initials: E
authors.lastname: Deligeoroglou
authors.forename: A
authors.initials: A
authors.lastname: Antoniou
authors.forename: I
authors.initials: I
authors.lastname: Lambrinoudaki
mesh_terms: D000368:Aged; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism*; D000069448:Denosumab / Q000494:pharmacology* / Q000627:therapeutic use; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism / Q000517:prevention & control; D017698:Postmenopause / Q000187:drug effects* / Q000378:metabolism*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab; D002118:Calcium